 |
| News |
 |
|
|
|
|
|
|
| |
Company
News, December 2005
CIS Pharma signs agreement with Biocydex to develop anti-cancer
compound
Based on Biocydex integrated cyclodextrin biotechnology platform CIS
Pharma will develop in co-operation with Biocydex a water soluble
form of an anti-cancer compound. CIS Pharma and Biocydex share the
IP rights for the compound with improved bioavalability properties.
Company News, September 2005
CIS Pharma welcomes its strategic partner OphthalmoPharma in Bubendorf
OphthalmoPharma, a specialty pharmaceutical company focusing on ophthalmology
treatment, has moved into its new offices in Bubendorf.
Company News, December 2004
CIS Pharma licenses to Ophthalmopharma water soluble Cyclosporin
A
CIS Pharma has out-licensed its water soluble Cyclosporin A development
to Ophthalmopharma. Ophthalmopharma aspires to become an innovator
in ophthalmology and to create new standards of care. Its strategy
is to build a pipeline and advance compounds through regulatory approval. |
|
| |
© 2003-2007 Chemisches Institut Schäfer AG. All rights reserved.
|
